Skip to content

Survey study, 2023

Is PMDD diagnosis associated with more severe depression and anxiety and lower well-being?

Yes. Women with probable PMDD had significantly higher depression and anxiety symptoms and lower well-being compared to those without PMDD, regardless of their menstrual cycle phase.

Moderate study design 112 adult women in Hungary with regular menstrual cycles, not using hormonal contraceptives

What they did

Cross-sectional online study in Hungary screening 393 women; 112 were included (excluded those with irregular cycles or using hormonal contraceptives). Women completed DSM-5 PMDD screening, depression, anxiety, and well-being questionnaires.

What they found

Of 112 women, 67 had probable PMDD and 45 did not. The PMDD group had significantly higher depression (F=19.394, p less than 0.001) and anxiety (F=17.714, p less than 0.001) and lower well-being (F=4.288, p=0.0442). A statistical model explained 29.2% of the likelihood of PMDD based on anxiety and depression levels.

What it means for you

Women with PMDD have significant mental health struggles beyond just cycle-related symptoms. Early recognition of these symptoms could help identify PMDD. The study was limited to Hungary and only included women with regular cycles not using hormonal birth control.

112

women studied

67

with probable PMDD

29.2%

variance in PMDD explained by anxiety and depression

About the study

Original title
Is even a probable premenstrual dysphoric disorder diagnosis associated with more severe anxio-depressive symptoms and lower well-being? A preliminary cross-sectional exploratory study
Authors
Kovács I, Pataki B, Kis B et al.
Journal
European psychiatry : the journal of the Association of European Psychiatrists
Year
2023
Study design
Survey study
What was tested
None; screening for probable PMDD diagnosis
Open access
Yes
Original abstract

Introduction Premenstrual dysphoric disorder (PMDD) is a newly introduced category in the 5th version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and is highly underdiagnosed worldwide, despite its strong connections to anxiodepressive symptom severity and perceived well-being. Objectives Firstly in Hungary, our aim was to: (a)assess whether even a probable PMDD diagnosis is associated with elevated levels of depressive and anxiety symptoms, and decreased perception of well-being on an adult women sample; (b)to evaluate whether women with a probable PMDD diagnosis report greater fluctuation of their affect during the different phases of their menstrual cycle; (c)to examine whether the elevated levels of anxiodepressive symptoms and lower well-being increase the statistical likelihood of having a probable PMDD diagnosis. Methods An online test battery was designed to examine probable PMDD diagnosis, severity of anxiodepressive symptoms and well-being. 393 adult women were screened for eligibility in the study (exclusion criteria involved: irregular cycle; use of hormonal contraceptives), from which 112 were included in the final analyses. DSM-5-Based Screening Tool for Women’s Perceptions of Premenstrual Symptoms, Beck’s Depression Inventory, Spielberger’s State Anxiety Inventory, and the WHO-5 Well-Being Index were assessed. Results Based on the DSM-5-Based Screening Tool, the sample was divided into 1)women with probable PMDD diagnosis (PMDD group,n=67) and 2)women without probable PMDD (nonPMDD group,n=45). Menstruation cycles were sorted into menstrual, from-menstruation-to-ovulation, early luteal and late luteal phases. The PMDD group exhibited significantly higher depressive (F(1;56,2)=19.394, p≤0.001) and anxiety (F(1;35,6)=17.714,p≤0.001) symptom severity and lower scores of well-being (F(1;44,3)=4.288,p=0.0442) compared to the nonPMDD group regardless of which menstrual cycle they were in. Binomial logistic regression model was used to test whether higher anxiodepressive symptoms and lower scores of well-being increase the likelihood of having PMDD: the model was significant (χ2(2)=27.287, p≤0.001), and it explained 29.2% of the variance in PMDD. Elevated levels of anxiety (B=0.058, S.E.=0.022, Waldχ2(1)=7.142, p=0.008,OR=1.060) and depressive (B=0.085,S.E.=0.031,Waldχ2(1)=7.480,p=0.006,OR=1.089) symptoms increased significantly the likelihood of having a probable PMDD diagnosis. Conclusions Women with even a probable PMDD diagnosis exhibited significantly elevated levels of anxiodepressive symptoms and lower scores of well-being regardless of which menstrual phase they were assessed in compared to women without meeting the criteria of the PMDD screening tool. These preliminary results underscore the need for prospective clinical studies of differences in affective symptoms exhibited in PMDD. Disclosure of Interest None Declared

Reproduced under CC-BY.

Topics